Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Endovia Health Sciences, Inc.SBEV · Entity 8508 | Director | July 31, 2025 | October 15, 2025 |
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Director | July 26, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Endovia Health Sciences, Inc.
Report date July 31, 2025 · Filed October 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2030-07-31 | Direct | 750,000 |
Reported balance
After 2025-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-31 · Grant · Acquired 750,000 · Balance 750,000 F1: The grant of the Issuer's warrants was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The warrants are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's warrants was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The warrants are fully vested.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 38,749 |
Reported balance
After 2026-07-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-26 · Grant · Acquired 33,500 · Balance 38,749 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 353 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 353 |
| Common StockSEC Table I · non-derivative | IndirectBy Richland Fund, LLC | 1,250 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,250 |
| Common StockSEC Table I · non-derivative | IndirectBy Directed Trust Company FBO Justin Yorke IRA | 496 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 496 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 12,000 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 12,000 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2026 Filed Jul 29, 2026 00:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 33,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001560 · form4.xml · derivative · entry 4 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,749 Underlying: Common Stock · 33,500 shares Expires not disclosed F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001472 · form4.xml · derivative · entry 4 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,249 Underlying: Common Stock · 203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of time-based service award. F1 · derivative.expiration_date: Distribution of time-based service award. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-26-001472 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of time-based service award. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001555 · form4.xml · derivative · entry 2 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001555 · form4.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 31, 2025 Filed Oct 15, 2025 20:16 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantWarrants · Derivative | 750,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001731122-25-001383 · ownership.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2030-07-31 F1 · security: The grant of the Issuer's warrants was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The warrants are fully vested. F1 · price: The grant of the Issuer's warrants was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The warrants are fully vested. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:16 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 175,299 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001205 · form4.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,505 Underlying: Common Stock · 175,299 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 125,999 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements. F2 · derivative.expiration_date: The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements. Read SEC document |
| January 29, 2025 Filed Feb 18, 2025 22:59 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantWarrants · Derivative | 6,200 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000897069-25-000296 · form4.xml · derivative · entry 5 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Directed Trust Company FBO Justin Yorke IRA Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires 2030-01-29 Read SEC document |
| January 29, 2025 Filed Feb 18, 2025 22:59 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantWarrants · Derivative | 12,400 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000897069-25-000296 · form4.xml · derivative · entry 4 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Directed Trust Company FBO Justin Yorke IRA Disclosed balance after: 12,400 Underlying: Common Stock · 12,400 shares Expires 2030-01-29 Read SEC document |
| January 27, 2025 Filed Jan 31, 2025 22:06 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 12,400 | $0.80 | $9,889.00 |
DisclosureSEC source: 0000897069-25-000153 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Directed Trust Company FBO Justin Yorke IRA Disclosed balance after: 12,400 Read SEC document |
| September 03, 2024 Filed Sep 18, 2024 20:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 31,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001866 · form4.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,206 Underlying: Common Stock · 31,206 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F1 · derivative.expiration_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 8,000 | $2.69 | $21,544.00 |
DisclosureSEC source: 0000897069-24-000227 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Richland Fund, LLC Disclosed balance after: 31,232 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 21, 2023 Filed Nov 28, 2023 21:13 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | OtherCommon Stock | 55,267 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001674 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Richland Fund, LLC Disclosed balance after: 464,623 F1 · kind: Represents a transfer of shares to a fund that the Reporting Person does not manage. As a result, the reporting person is no longer deemed to be the beneficial owner of such shares. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 21:56 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 6,000 | $0.30 | $1,800.00 |
DisclosureSEC source: 0000897069-23-001462 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,729 Read SEC document |
| October 12, 2023 Filed Oct 23, 2023 21:31 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 6,000 | $0.30 | $1,800.00 |
DisclosureSEC source: 0000897069-23-001499 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,729 F1 · balance_after: Amendment filed solely to correct the amount directly owned reported on the Form 4 filed October 12, 2023 and the Form 4 filed on October 10/10/2023. Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 20:58 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 12,000 | $0.21 | $2,520.00 |
DisclosureSEC source: 0000897069-23-001440 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,729 Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 101,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001004 · form4.xml · derivative · entry 4 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,365 Underlying: Common Stock · 101,365 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 23,636 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001004 · form4.xml · derivative · entry 3 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Vesting of time-based restricted shares. F1 · derivative.expiration_date: Vesting of time-based restricted shares. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 23,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-23-001004 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| April 24, 2023 Filed May 15, 2023 20:30 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantStock options · Derivative | 125,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001731122-23-000935 · ownership.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common stock · 125,000 shares Expires 2033-04-05 F1 · derivative.exercise_date: The options are being issued in connection with serving on the board of directors of SBEV, pursuant to the 2020 Long-Term Incentive Compensation Plan. 10,417 options will vest on the 5th day of each month starting May 2023 until December 2023 and 10,416 options will vest on the 5th day of each month starting January 2024 until April 2024. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000329 · doc1.xml · derivative · entry 3 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 18,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-000329 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,093 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| August 05, 2022 Filed Jan 4, 2023 22:29 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-000303 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. F2 · balance_after: Previous filing inadvertently underreported shares beneficially owned by the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:54 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 4,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-008006 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,716 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| March 31, 2022 Filed Aug 9, 2022 20:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 4,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015312 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,716 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 21:45 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | SaleCommon Stock | 1,854 | $3.30 | $6,118.20 |
DisclosureSEC source: 0001567619-22-002079 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC Disclosed balance after: 532,563 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.37, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 01, 2022 Filed Apr 20, 2022 01:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 18,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008684 · doc1.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,377 Underlying: Common Stock · 18,208 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 100% on December 31, 2022. F1 · derivative.expiration_date: Restricted stock units vest 100% on December 31, 2022. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | SaleCommon Stock | 4,200 | $4.71 | $19,783.68 |
DisclosureSEC source: 0001567619-21-021710 · doc1.xml · nonDerivative · entry 2 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC Disclosed balance after: 534,417 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.5601 to $4.80, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | SaleCommon Stock | 5,500 | $4.84 | $26,599.10 |
DisclosureSEC source: 0001567619-21-021710 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC Disclosed balance after: 538,617 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8001 to $5.01, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 30, 2021 Filed Apr 1, 2022 01:42 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantOption (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001731122-22-000655 · ownership.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2026-09-30 F1 · derivative.exercise_date: Two-thirds of the Options vested on September 30, 2021, and one-third of the Options vest on September 30, 2022. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:44 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014756 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,875 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| August 05, 2021 Filed Sep 1, 2021 20:41 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-016570 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,323 F1 · price: Vesting of time-based restricted shares. F2 · balance_after: The previous filing overstated the number of securities directly owned by the reporting person and understated the number of securities indirectly owned by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | SaleCommon Stock | 9,700 | $9.42 | $91,374.00 |
DisclosureSEC source: 0001567619-21-008151 · doc1.xml · nonDerivative · entry 2 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC Disclosed balance after: 248,272 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.31 to $9.50, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | SaleCommon Stock | 6,500 | $9.86 | $64,090.00 |
DisclosureSEC source: 0001567619-21-008151 · doc1.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC Disclosed balance after: 257,972 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.65 to $10.15, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 16, 2020 Filed Oct 19, 2020 22:30 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantWarrants (Right to Buy) · Derivative | 166,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001731122-20-001059 · ownership.xml · derivative · entry 3 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock · 166,666 shares Expires 2027-10-15 F1 · price: Not applicable Read SEC document |
| October 16, 2020 Filed Oct 19, 2020 22:30 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantWarrants (Right to Buy) · Derivative | 166,667 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001731122-20-001059 · ownership.xml · derivative · entry 2 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 166,667 shares Expires 2026-10-15 F1 · price: Not applicable Read SEC document |
| October 16, 2020 Filed Oct 19, 2020 22:30 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantWarrants (Right to Buy) · Derivative | 166,667 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001731122-20-001059 · ownership.xml · derivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 166,667 shares Expires 2025-10-15 F1 · price: Not applicable Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.